Sylvie Grégoire

Sylvie Grégoire has served as Chair of Abivax's Board and an independent director since July 2024, and was appointed Board Chair in June 2025. A pharmaceutical and biotech executive with over 30 years in international leadership roles spanning late-stage development, financing and commercial expansion, she is co-founder and was Executive Chair of EIP Pharma Inc. (Boston), which transitioned into NASDAQ-listed CervoMed, developing a disease-modifying treatment for Dementia with Lewy Bodies. She has previously served on the boards of Cubist, Glycofi, Vifor Pharma, Revvity and Novo Nordisk and chaired the boards of IDM Pharma, Corvidia and CervoMed; she currently serves on the boards of CervoMed and F2G Ltd. She holds a BA in Pharmacy from Laval University in Canada and a Pharmacy Doctorate from the State University of New York at Buffalo. She chairs the Nomination and Governance Committee and is a member of the Audit Committee.

Director Compensation

You're subscribed.

Thanks for signing up.